Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
YETI, Gilead, Dick's, FedEx and Amazon highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
YETI, Gilead, Dick's, FedEx and Amazon highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Gilead Sciences (GILD)
by Madeleine Johnson
The potential for revenue growth looks shaky for this biotech giant.
Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
by Zacks Equity Research
Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $65.75, moving +1.42% from the previous trading session.
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
by Zacks Equity Research
Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
by Zacks Equity Research
Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
Why Is Gilead (GILD) Down 4.9% Since Last Earnings Report?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intercept (ICPT) Up on Q4 Revenue Beat, NASH Study in Focus
by Zacks Equity Research
Intercept's (ICPT) Q4 revenues top estimates owing to strong Ocaliva sales, driven by sales force expansion and growth in its foreign geographies.
Nektar (NKTR) Q4 Earnings Beat, NKTR-181 Review Extended
by Zacks Equity Research
Nektar's (NKTR) earnings and sales beat estimates in the fourth quarter. The FDA extends the review period for NKTR-181 NDA by three months.
The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis
Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More
by Zacks Equity Research
Key highlights of the past week are regulatory and pipeline developments along with research collaboration deals.
Intercept Reports Positive Top-Line Data for NASH, Shares Up
by Zacks Equity Research
Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
by Sanghamitra Saha
Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.
Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
by Zacks Equity Research
Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.
Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails
by Zacks Equity Research
Gilead (GILD) suffers a setback as its phase III study on pipeline candidate, selonsertib, in patients with compensated cirrhosis (F4) due to NASH fails to meet goal.
The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO
Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink
by Zacks Equity Research
Key highlights of the week were the fourth-quarter results by biotech bigwigs Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Celgene (CELG).
UnitedHealth, MercadoLibre, Alphabet and Gilead highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
UnitedHealth, MercadoLibre, Alphabet and Gilead highlighted as Zacks Bull and Bear of the Day
Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
A mixed fourth-quarter for biotech bigwig Gilead as it misses on earnings but beat on revenues.
Alphabet (GOOGL) Outperforms Estimates, Gilead (GILD) Mixed
by Mark Vickery
Google parent Alphabet posted Q4 earnings that came in stronger than expected, while Gilead's report was mixed with lower-than-expected earnings.
Gilead Sciences (GILD) Misses Q4 Earnings Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of -15.29% and 4.81%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales?
by Zacks Equity Research
Gilead (GILD) is scheduled to report fourth-quarter results on Feb 4. Investors will likely focus on the strong HIV franchise and other pipeline updates.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $69.83, moving +0.34% from the previous trading session.
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's Behind the Biotech ETF Rally to Start 2019?
by Sanghamitra Saha
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.